Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 80

1.

Ex-Vivo Treatment of Tumor Tissue Slices as a Predictive Preclinical Method to Evaluate Targeted Therapies for Patients with Renal Carcinoma.

Roelants C, Pillet C, Franquet Q, Sarrazin C, Peilleron N, Giacosa S, Guyon L, Fontanell A, Fiard G, Long JA, Descotes JL, Cochet C, Filhol O.

Cancers (Basel). 2020 Jan 17;12(1). pii: E232. doi: 10.3390/cancers12010232.

2.

Protein kinase CK2 contributes to placental development: physiological and pathological implications.

Abi Nahed R, Reynaud D, Lemaitre N, Lartigue S, Roelants C, Vaiman D, Benharouga M, Cochet C, Filhol O, Alfaidy N.

J Mol Med (Berl). 2020 Jan;98(1):123-133. doi: 10.1007/s00109-019-01855-0. Epub 2019 Dec 12.

PMID:
31832700
3.

Discovery of holoenzyme-disrupting chemicals as substrate-selective CK2 inhibitors.

Kufareva I, Bestgen B, Brear P, Prudent R, Laudet B, Moucadel V, Ettaoussi M, Sautel CF, Krimm I, Engel M, Filhol O, Borgne ML, Lomberget T, Cochet C, Abagyan R.

Sci Rep. 2019 Nov 4;9(1):15893. doi: 10.1038/s41598-019-52141-5.

4.

Targeting AU-rich element-mediated mRNA decay with a truncated active form of the zinc-finger protein TIS11b/BRF1 impairs major hallmarks of mammary tumorigenesis.

Rataj F, Planel S, Denis J, Roelants C, Filhol O, Guyon L, Feige JJ, Cherradi N.

Oncogene. 2019 Jun;38(26):5174-5190. doi: 10.1038/s41388-019-0784-8. Epub 2019 Mar 26.

PMID:
30914800
5.

2-Aminothiazole Derivatives as Selective Allosteric Modulators of the Protein Kinase CK2. 2. Structure-Based Optimization and Investigation of Effects Specific to the Allosteric Mode of Action.

Bestgen B, Kufareva I, Seetoh W, Abell C, Hartmann RW, Abagyan R, Le Borgne M, Filhol O, Cochet C, Lomberget T, Engel M.

J Med Chem. 2019 Feb 28;62(4):1817-1836. doi: 10.1021/acs.jmedchem.8b01765. Epub 2019 Feb 13.

PMID:
30689946
6.

Combined inhibition of PI3K and Src kinases demonstrates synergistic therapeutic efficacy in clear-cell renal carcinoma.

Roelants C, Giacosa S, Pillet C, Bussat R, Champelovier P, Bastien O, Guyon L, Arnoux V, Cochet C, Filhol O.

Oncotarget. 2018 Jul 10;9(53):30066-30078. doi: 10.18632/oncotarget.25700. eCollection 2018 Jul 10. Erratum in: Oncotarget. 2019 Mar 15;10(22):2236.

7.

The tyrosine-kinase inhibitor sunitinib targets vascular endothelial (VE)-cadherin: a marker of response to antitumoural treatment in metastatic renal cell carcinoma.

Polena H, Creuzet J, Dufies M, Sidibé A, Khalil-Mgharbel A, Salomon A, Deroux A, Quesada JL, Roelants C, Filhol O, Cochet C, Blanc E, Ferlay-Segura C, Borchiellini D, Ferrero JM, Escudier B, Négrier S, Pages G, Vilgrain I.

Br J Cancer. 2018 May;118(9):1179-1188. doi: 10.1038/s41416-018-0054-5. Epub 2018 Mar 22.

8.

Stem Cell-Like Properties of CK2β-down Regulated Mammary Cells.

Duchemin-Pelletier E, Baulard M, Spreux E, Prioux M, Burute M, Mograbi B, Guyon L, Théry M, Cochet C, Filhol O.

Cancers (Basel). 2017 Aug 31;9(9). pii: E114. doi: 10.3390/cancers9090114.

9.

The size-speed-force relationship governs migratory cell response to tumorigenic factors.

Leal-Egaña A, Letort G, Martiel JL, Christ A, Vignaud T, Roelants C, Filhol O, Théry M.

Mol Biol Cell. 2017 Jun 15;28(12):1612-1621. doi: 10.1091/mbc.E16-10-0694. Epub 2017 Apr 20.

10.

In Search of Small Molecule Inhibitors Targeting the Flexible CK2 Subunit Interface.

Bestgen B, Belaid-Choucair Z, Lomberget T, Le Borgne M, Filhol O, Cochet C.

Pharmaceuticals (Basel). 2017 Feb 3;10(1). pii: E16. doi: 10.3390/ph10010016.

11.

Polarity Reversal by Centrosome Repositioning Primes Cell Scattering during Epithelial-to-Mesenchymal Transition.

Burute M, Prioux M, Blin G, Truchet S, Letort G, Tseng Q, Bessy T, Lowell S, Young J, Filhol O, Théry M.

Dev Cell. 2017 Jan 23;40(2):168-184. doi: 10.1016/j.devcel.2016.12.004. Epub 2016 Dec 29.

12.

Protein kinase CK2 controls T-cell polarization through dendritic cell activation in response to contact sensitizers.

de Bourayne M, Gallais Y, El Ali Z, Rousseau P, Damiens MH, Cochet C, Filhol O, Chollet-Martin S, Pallardy M, Kerdine-Römer S.

J Leukoc Biol. 2017 Mar;101(3):703-715. doi: 10.1189/jlb.3A0715-320RR. Epub 2016 Oct 5.

PMID:
27707883
13.

DARPP-32 interaction with adducin may mediate rapid environmental effects on striatal neurons.

Engmann O, Giralt A, Gervasi N, Marion-Poll L, Gasmi L, Filhol O, Picciotto MR, Gilligan D, Greengard P, Nairn AC, Hervé D, Girault JA.

Nat Commun. 2015 Dec 7;6:10099. doi: 10.1038/ncomms10099.

14.

Modulatory role of the anti-apoptotic protein kinase CK2 in the sub-cellular localization of Fas associated death domain protein (FADD).

Vilmont V, Filhol O, Hesse AM, Couté Y, Hue C, Rémy-Tourneur L, Mistou S, Cochet C, Chiocchia G.

Biochim Biophys Acta. 2015 Nov;1853(11 Pt A):2885-96. doi: 10.1016/j.bbamcr.2015.08.001. Epub 2015 Aug 5.

15.

Protein kinase CK2 in breast cancer: the CK2β regulatory subunit takes center stage in epithelial plasticity.

Filhol O, Giacosa S, Wallez Y, Cochet C.

Cell Mol Life Sci. 2015 Sep;72(17):3305-22. doi: 10.1007/s00018-015-1929-8. Epub 2015 May 20. Review.

PMID:
25990538
16.

FRET-based screening assay using small-molecule photoluminescent probes in lysate of cells overexpressing RFP-fused protein kinases.

Manoharan GB, Enkvist E, Kasari M, Viht K, Zenn M, Prinz A, Filhol O, Herberg FW, Uri A.

Anal Biochem. 2015 Jul 15;481:10-7. doi: 10.1016/j.ab.2015.04.009. Epub 2015 Apr 10.

PMID:
25866074
17.

CK2 accumulation at the axon initial segment depends on sodium channel Nav1.

Hien YE, Montersino A, Castets F, Leterrier C, Filhol O, Vacher H, Dargent B.

FEBS Lett. 2014 Sep 17;588(18):3403-8. doi: 10.1016/j.febslet.2014.07.032. Epub 2014 Aug 7.

18.

Regulation of the proapoptotic functions of prostate apoptosis response-4 (Par-4) by casein kinase 2 in prostate cancer cells.

de Thonel A, Hazoumé A, Kochin V, Isoniemi K, Jego G, Fourmaux E, Hammann A, Mjahed H, Filhol O, Micheau O, Rocchi P, Mezger V, Eriksson JE, Rangnekar VM, Garrido C.

Cell Death Dis. 2014 Jan 23;5:e1016. doi: 10.1038/cddis.2013.532.

19.

DSIR: assessing the design of highly potent siRNA by testing a set of cancer-relevant target genes.

Filhol O, Ciais D, Lajaunie C, Charbonnier P, Foveau N, Vert JP, Vandenbrouck Y.

PLoS One. 2012;7(10):e48057. doi: 10.1371/journal.pone.0048057. Epub 2012 Oct 30.

20.

Pharmacological inhibition of LIM kinase stabilizes microtubules and inhibits neoplastic growth.

Prudent R, Vassal-Stermann E, Nguyen CH, Pillet C, Martinez A, Prunier C, Barette C, Soleilhac E, Filhol O, Beghin A, Valdameri G, Honoré S, Aci-Sèche S, Grierson D, Antonipillai J, Li R, Di Pietro A, Dumontet C, Braguer D, Florent JC, Knapp S, Bernard O, Lafanechère L.

Cancer Res. 2012 Sep 1;72(17):4429-39. Epub 2012 Jul 3.

21.

Unbalanced expression of CK2 kinase subunits is sufficient to drive epithelial-to-mesenchymal transition by Snail1 induction.

Deshiere A, Duchemin-Pelletier E, Spreux E, Ciais D, Combes F, Vandenbrouck Y, Couté Y, Mikaelian I, Giusiano S, Charpin C, Cochet C, Filhol O.

Oncogene. 2013 Mar 14;32(11):1373-83. doi: 10.1038/onc.2012.165. Epub 2012 May 7.

PMID:
22562247
22.

Spatial organization of the extracellular matrix regulates cell-cell junction positioning.

Tseng Q, Duchemin-Pelletier E, Deshiere A, Balland M, Guillou H, Filhol O, Théry M.

Proc Natl Acad Sci U S A. 2012 Jan 31;109(5):1506-11. doi: 10.1073/pnas.1106377109. Epub 2012 Jan 17.

23.

Structure-function analysis of the beta regulatory subunit of protein kinase CK2 by targeting embryonic stem cell.

Ziercher L, Filhol O, Laudet B, Prudent R, Cochet C, Buchou T.

Mol Cell Biochem. 2011 Oct;356(1-2):75-81. doi: 10.1007/s11010-011-0955-6. Epub 2011 Aug 23.

PMID:
21861102
24.

Regulation of epithelial to mesenchymal transition: CK2β on stage.

Deshiere A, Duchemin-Pelletier E, Spreux E, Ciais D, Forcet C, Cochet C, Filhol O.

Mol Cell Biochem. 2011 Oct;356(1-2):11-20. doi: 10.1007/s11010-011-0942-y. Epub 2011 Jul 14.

PMID:
21755461
25.

Protein kinases curb cell death.

Filhol O, Cochet C.

Sci Signal. 2011 May 10;4(172):pe26. doi: 10.1126/scisignal.2001921.

PMID:
21558553
26.

A new micropatterning method of soft substrates reveals that different tumorigenic signals can promote or reduce cell contraction levels.

Tseng Q, Wang I, Duchemin-Pelletier E, Azioune A, Carpi N, Gao J, Filhol O, Piel M, Théry M, Balland M.

Lab Chip. 2011 Jul 7;11(13):2231-40. doi: 10.1039/c0lc00641f. Epub 2011 Apr 26.

PMID:
21523273
27.

Protein kinase CK2α subunit over-expression correlates with metastatic risk in breast carcinomas: quantitative immunohistochemistry in tissue microarrays.

Giusiano S, Cochet C, Filhol O, Duchemin-Pelletier E, Secq V, Bonnier P, Carcopino X, Boubli L, Birnbaum D, Garcia S, Iovanna J, Charpin C.

Eur J Cancer. 2011 Mar;47(5):792-801. doi: 10.1016/j.ejca.2010.11.028. Epub 2010 Dec 29.

PMID:
21194925
28.

Antitumor activity of pyridocarbazole and benzopyridoindole derivatives that inhibit protein kinase CK2.

Prudent R, Moucadel V, Nguyen CH, Barette C, Schmidt F, Florent JC, Lafanechère L, Sautel CF, Duchemin-Pelletier E, Spreux E, Filhol O, Reiser JB, Cochet C.

Cancer Res. 2010 Dec 1;70(23):9865-74. doi: 10.1158/0008-5472.CAN-10-0917. Epub 2010 Nov 30.

29.

In vitro and in vivo assays of protein kinase CK2 activity.

Prudent R, Sautel CF, Moucadel V, Laudet B, Filhol O, Cochet C.

Methods Enzymol. 2010;485:597-610. doi: 10.1016/B978-0-12-381296-4.00031-2.

PMID:
21050938
30.

Protein kinase CK2 in health and disease: Cellular functions of protein kinase CK2: a dynamic affair.

Filhol O, Cochet C.

Cell Mol Life Sci. 2009 Jun;66(11-12):1830-9. doi: 10.1007/s00018-009-9151-1. Review.

PMID:
19387551
31.

Protein kinase CK2 and cell polarity.

Deshière A, Theis-Febvre N, Martel V, Cochet C, Filhol O.

Mol Cell Biochem. 2008 Sep;316(1-2):107-13. doi: 10.1007/s11010-008-9845-y. Epub 2008 Jun 28.

PMID:
18587631
32.

Identification of chemical inhibitors of protein-kinase CK2 subunit interaction.

Laudet B, Moucadel V, Prudent R, Filhol O, Wong YS, Royer D, Cochet C.

Mol Cell Biochem. 2008 Sep;316(1-2):63-9. doi: 10.1007/s11010-008-9821-6. Epub 2008 Jun 14.

PMID:
18553057
33.

A phosphatase cascade by which rewarding stimuli control nucleosomal response.

Stipanovich A, Valjent E, Matamales M, Nishi A, Ahn JH, Maroteaux M, Bertran-Gonzalez J, Brami-Cherrier K, Enslen H, Corbillé AG, Filhol O, Nairn AC, Greengard P, Hervé D, Girault JA.

Nature. 2008 Jun 12;453(7197):879-84. doi: 10.1038/nature06994. Epub 2008 May 21.

34.

Structure-based design of small peptide inhibitors of protein kinase CK2 subunit interaction.

Laudet B, Barette C, Dulery V, Renaudet O, Dumy P, Metz A, Prudent R, Deshiere A, Dideberg O, Filhol O, Cochet C.

Biochem J. 2007 Dec 15;408(3):363-73.

35.

Protein kinase CK2 phosphorylation of EB2 regulates its function in the production of Epstein-Barr virus infectious viral particles.

Medina-Palazon C, Gruffat H, Mure F, Filhol O, Vingtdeux-Didier V, Drobecq H, Cochet C, Sergeant N, Sergeant A, Manet E.

J Virol. 2007 Nov;81(21):11850-60. Epub 2007 Aug 15.

36.

HIRIP3 is a nuclear phosphoprotein interacting with and phosphorylated by the serine-threonine kinase CK2.

Assrir N, Filhol O, Galisson F, Lipinski M.

Biol Chem. 2007 Apr;388(4):391-8.

PMID:
17391060
37.

[Therapeutic agents targetting protein-protein interactions: myth or reality?].

Laudet B, Prudent R, Filhol O, Cochet C.

Med Sci (Paris). 2007 Mar;23(3):273-8. Review. French.

38.

Nuclear localization of protein kinase CK2 catalytic subunit (CK2alpha) is associated with poor prognostic factors in human prostate cancer.

Laramas M, Pasquier D, Filhol O, Ringeisen F, Descotes JL, Cochet C.

Eur J Cancer. 2007 Mar;43(5):928-34. Epub 2007 Jan 30.

PMID:
17267203
39.
40.

Highlighting protein kinase CK2 movement in living cells.

Theis-Febvre N, Martel V, Laudet B, Souchier C, Grunwald D, Cochet C, Filhol O.

Mol Cell Biochem. 2005 Jun;274(1-2):15-22.

PMID:
16335524
41.

The antiapoptotic protein ICBP90 is a target for protein kinase 2.

Bronner C, Trotzier MA, Filhol O, Cochet C, Rochette-Egly C, Schöller-Guinard M, Klein JP, Mousli M.

Ann N Y Acad Sci. 2004 Dec;1030:355-60.

PMID:
15659817
42.

Protein kinase CK2: a new view of an old molecular complex.

Filhol O, Martiel JL, Cochet C.

EMBO Rep. 2004 Apr;5(4):351-5.

43.

Live-cell fluorescence imaging reveals the dynamics of protein kinase CK2 individual subunits.

Filhol O, Nueda A, Martel V, Gerber-Scokaert D, Benitez MJ, Souchier C, Saoudi Y, Cochet C.

Mol Cell Biol. 2003 Feb;23(3):975-87.

44.

Protein kinase CK2 regulates CDC25B phosphatase activity.

Theis-Febvre N, Filhol O, Froment C, Cazales M, Cochet C, Monsarrat B, Ducommun B, Baldin V.

Oncogene. 2003 Jan 16;22(2):220-32.

PMID:
12527891
45.

Dynamic localization/association of protein kinase CK2 subunits in living cells: a role in its cellular regulation?

Martel V, Filhol O, Nueda A, Cochet C.

Ann N Y Acad Sci. 2002 Nov;973:272-7.

PMID:
12485876
46.

Engrailed homeoprotein secretion is a regulated process.

Maizel A, Tassetto M, Filhol O, Cochet C, Prochiantz A, Joliot A.

Development. 2002 Aug;129(15):3545-53.

47.

[Protein kinase CK2 and cancer: further clues are accumulating].

Filhol O, Cochet C.

Bull Cancer. 2002 Mar;89(3):261-5. Review. French.

48.

Adenovirus infection targets the cellular protein kinase CK2 and RNA-activated protein kinase (PKR) into viral inclusions of the cell nucleus.

Souquere-Besse S, Pichard E, Filhol O, Legrand V, Rosa-Calatrava M, Hovanessian AG, Cochet C, Puvion-Dutilleul F.

Microsc Res Tech. 2002 Mar 15;56(6):465-78.

PMID:
11921349
49.

Visualization and molecular analysis of nuclear import of protein kinase CK2 subunits in living cells.

Martel V, Filhol O, Nueda A, Gerber D, Benitez MJ, Cochet C.

Mol Cell Biochem. 2001 Nov;227(1-2):81-90.

PMID:
11827178
50.

Mitotic phosphorylation of DNA topoisomerase II alpha by protein kinase CK2 creates the MPM-2 phosphoepitope on Ser-1469.

Escargueil AE, Plisov SY, Filhol O, Cochet C, Larsen AK.

J Biol Chem. 2000 Nov 3;275(44):34710-8.

Supplemental Content

Loading ...
Support Center